News
Public · Published
Piper Sandler maintains Moderna at Overweight, raises price target to $305 from $230
Piper Sandler maintained its Overweight rating on Moderna and raised its price target to $305 from $230. The new target is 32.6% higher and implies 20.0% upside from the Nov. 6 closing price of $254.19.
Published:
Updated:
What happened
Piper Sandler maintained its Overweight rating on Moderna and raised its price target to $305 from $230. The new target is 32.6% higher and implies 20.0% upside from the Nov. 6 closing price of $254.19.
Confirmed
Global impact / market context
The higher target may shape investor expectations and trading, but it does not itself change Moderna’s sales, costs, or cash available. A concrete business effect would require investors’ response to influence the company’s ability to raise funds or its choices about spending.
Analyst inference
The article reports four recent analyst price targets ranging from $90 to $230, while Piper Sandler’s new target is $305. This spread shows disagreement among analysts; whether that changes investor positioning depends on how investors weigh the revised estimate against other views.
Analyst inference
What to watch
- Look for an explanation from Piper Sandler for the higher target; the article gives no reason, so its assumptions about Moderna’s future prospects are not stated. Analyst inference
- Check whether other analysts raise their targets toward $305; a broader shift could change investor expectations and, in turn, affect demand for Moderna shares. Analyst inference
- Compare the share price with the article’s $254.19 Nov. 6 close; the stated 20.0% upside is calculated from that closing price, not a guaranteed return. Confirmed
Evidence
- Original source link unavailable